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Abstract 
Review on Male breast cancer, with data on clinics, 
and the genes involved.  
Keywords 
Male breast cancer; ERBB2; FGFR1; BRCA1; 
PTEN; ATM; CDH1; BRCA2; PALB2; CHEK2; 
AR; CYP17; PIK3CA; GATA3; TP53; CCND1 
Identity 
Other names 
Breast Neoplasms, Male 
Breast Carcinoma, Male 
Phylum 
Female organs:Breast tumors: carcinoma 
Classification 
Male breast cancer (MBC) is extremely rare and 
accounts for less than 1% of all  (Anderson et al., 
2010). Only 0.2% of all cancer types in men is a 
breast cancer (in women, this is 31%). The annual 
incidence is 1/100.000 men (Ly et al., 2013). 
While thought traditionally to be similar to post-
menopausal female breast cancer (FBC), emerging 
evidence suggests that MBC may be different, with 
unique molecular subtypes (Johansson et al., 2014). 
Two distinct subgroups of MBC, luminal M1 and 
luminal M2, have been identified which differ from 
the well-established intrinsic subtypes of breast 
cancer in women. These novel subgroups appear 
unique to MBC, with the luminal M2 subgroup 
demonstrating higher immune response and ER 
signaling, and luminal M1 tumors displaying more 
tumor invasion and metastasis, proliferation and 
HER2 signaling. MBCs of the luminal M1 subgroup 
display more aggressive features than other MBC 
tumors.  
The frequency of histological subtypes (per WHO 
2012) differs between males and females, with 
invasive carcinomas of no special type (  ) being by 
far the most common subtype (> 90%) (Deb et al., 
2016). This is followed by  and  which, 
proportionately, are seen more frequently in males 
when compared to females. Conversely, in men,  are 
less common and represent only 1% of all male 
breast cancers. Other less common carcinoma 
subtypes seen in males also include , ,  and . The 
majority of MBC present as symptomatic invasive 
disease. The early detection of the pre-invasive form, 
(DCIS), is rare in the absence of effective breast 
screening in men (Anderson and Devesa, 2005). 
(LCIS) has been described mostly coexisting with 
invasive lobular carcinoma. 
MBCs more frequently express estrogen receptor 
(ER) and progesterone receptor (PR) than FBCs (ER 
> 90 versus 76%, PR > 75 versus 60% in FBC). 
HER2 amplification and overexpression is less 
frequent in males when compared to females (Deb et 
al., 2016). Preliminary results from 1483 MBC cases 
amassed by EORTC10085, TBCRC, BIG and the 
NABCG International Male Breast Cancer Program 
were reported by Cardoso et al. in 2014 (Cardoso et 
al., 2014). Of the tumors analysed, 92% were ER+, 
35% PR+, and only 5% HER2+. Subsequently, the 
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most common phenotype seen in MBC is the 
luminal-like (ER+ and/or PR+, HER2-) subtype with 
only occasional HER2-driven (ER- and PR- 
,HER2+) and basal-like subtypes [ER-, PR-, HER2-
]. Within the luminal-like subtype, there appears to 
be an overrepresentation of the luminal B-like 
category (Ki67 high) versus the luminal A-like 
category (Ki67 low), compared to FBC (Piscuoglio 
et al., 2016; Kornegoor et al., 2012a). 
Clinics and pathology 
Disease 
MBC is usually discovered (75%) as a painless 
retroareolar mass. Other presenting features include 
nipple retraction (9%), nipple discharge (6%), 
ulceration (6%) and pain (5%)(Fentiman, 2009).The 
rarity of MBC usually results in a delay of 
recognition and diagnosis. Consequently, MBC is 
often diagnosed at older age and with a more 
advanced clinical stage compared to FBC (more than 
40% have stage III or IV disease) (Fentiman et al., 
2006). Male and female patients with breast cancer 
are staged similarly according to the American Joint 
committee on Cancer (AJCC) or Union for 
International Cancer Control (UICC) guidelines. 
Etiology 
The current literature suggests that genetic factors 
including BRCA2 mutations, family history, age, 
androgen/estrogen imbalance, and environmental 
exposures may predispose to male breast cancer 
(Ferzoco and Ruddy, 2016). Like many cancers, 
MBC is an age-related malignancy, with incidence 
peaking in the mid-60s. Men diagnosed with breast 
cancer tend to be 5-10 years older than women 
diagnosed with breast cancer. Those with a family 
history of breast cancer have two to three times the 
risk of developing breast cancer themselves. This 
risk increases when multiple family members are 
affected. About 20 % of men with breast cancer have 
at least one first-degree female relative with breast 
cancer. BRCA1/2 mutations, and specifically 
BRCA2 mutations, are a clear causal factor for 
MBC. Multiple population-based studies have 
shown that 4-15 % of men with breast cancer carry 
deleterious BRCA2 mutations and less than 5 % 
carry a BRCA1 mutation (Ferzoco and Ruddy, 
2016). Mutations in CHEK2 may confer an 
increased risk of MBC too, although the relative risk 
of these mutations, particularly CHEK2*1100delC, 
are uncertain (Neuhausen et al., 2004). Mutations 
within the DNA binding domain of androgen 
receptor have been described in MBC patients and 
there is a link between the cytochrome p540c17α 
enzyme (CYP17A1) and MBC. See section Genetics 
for more gene aberration specific information. 
Hormonal imbalance, in particularly the excess of 
estrogen and a deficiency of testosterone, can confer 
heightened risk for the development of MBC. This 
imbalance can be caused by testicular abnormalities, 
liver diseases/cirrhosis and obesity. Furthermore, 
having Klinefelter's syndrome (characterized by one 
or more additional X chromosomes, testicular 
dysgenesis, gynecomastia, low testosterone 
concentrations and increased gonadotrophins) is 
strongly associated with MBC, with a 20-50 times 
higher risk compared to the general male population 
(Hultborn et al., 1997). Gynecomastia on the other 
hand, caused by an imbalance in estrogen and 
androgen levels, is not a risk factor for MBC (Ewertz 
et al., 2001; Krause, 2004). Interfering with estrogen 
or androgen levels by administration of estrogen or 
anti-androgens to trans-sexuals and for treatment of 
prostate cancer have been implicated as causative 
factors in MBC (Ganly and Taylor, 1995; 
Karamanakos et al., 2004; Gooren et al., 2013). 
Radiation exposure increases risk of breast cancer in 
both women and men. Small numbers of chest X-
rays do not, but prolonged exposure to radiographs 
or radiotherapy may be harmful (Fentiman, 2009). 
Environmental exposures including electromagnetic 
radiation, heat, polycyclic aromatic hydrocarbons, 
alcohol, and red meat have been studied in relation 
to male breast cancer, but none have convincingly 
found to be associated with incidence across studies 
(Ottini et al., 2010). 
Epidemiology 
In Western countries MBC comprises less than 1 % 
of all cancers in men. Worldwide variation of MBC 
resembles that of FBC with higher incidences in 
North America and Europe and lower incidences in 
Asia (Ottini et al., 2010). A substantial higher rate of 
MBC cases has been reported in Africa. The 
incidence rates of MBC in Uganda and Zambia for 
example are 5% and 15%, respectively 
(Bhagwandeen, 1972; Ojara, 1978). Similar to FBC, 
MBC incidence in Japan is significantly lower than 
the average (IARC, 1976). Recent epidemiological 
studies indicate that MBC incidence is rising 
(Giordano et al., 2004; Stang and Thomssen, 2008; 
Speirs and Shaaban, 2009). 
The incidence and mortality of MBC increase with 
age. The bimodal age distribution seen in FBC 
patients is absent in MBC patients. Median age at 
diagnosis is 68.5 years with 5% of patients 
diagnosed with distant metastases (M1). Of patients 
presenting without distant metastases (M0), 60% are 
lymph node negative and 51% have T1 tumors at 
diagnosis (tumor size 2 centimeters or less) (Cardoso 
et al., 2014). Breast cancer mortality and survival 
rates have improved significantly over time for both 
MBC and FBC, but progress for men has lagged 
behind that for women (Anderson et al., 2010). 
Overall survival, especially 5-year overall survival, 
is lower compared to female patients because of the 
older age at diagnosis and more advanced stage at 
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presentation (Giordano et al., 2004). Disease specific 
survival rates are higher than overall survival rates 
due to older average age and deaths from other 
comorbid diseases (Giordano, 2005). 
Pathology 
The Pathologist assesses resection margins, lymph 
node status, tumor size, tumor grade, mitotic 
activity, histological subtype, lymphovascular 
invasion, hormonal receptor status (by 
immunohistochemistry) and HER2 status. As 
already mentioned in the section "Classification", the 
majority of MBC are invasive ductal carcinomas (of 
no special type) (> 90%) (Deb et al., 2016). Lobular 
carcinomas are less common and represent only 1-
2% of all MBCs. MBCs more frequently express ER 
and PR than FBC (ER > 90% versus 76%, PR > 75% 
versus 60% in FBC). HER2 amplification and 
overexpression is less frequent in males (5%) 
compared to females (10-15%) (Cardoso et al., 2014; 
Deb et al., 2016). Subsequently, the most common 
phenotype seen in MBC is the luminal-like (>95%; 
ER+ and/or PR+, HER2-) subtype with only 
occasional HER2-driven-like (ER- and PR-, 
HER2+) and basal-like (triple negative) subtypes 
[ER-, PR-, HER2-]. Within the luminal-like subtype, 
MBC are more frequently luminal B-like (Ki67 
high) compared to FBC (Piscuoglio et al., 2016; 
Kornegoor et al., 2012a). Fibrotic focus is seen in 
25% of MBC and correlated to hypoxia-inducible 
factor-1α overexpression (Kornegoor et al., 2012b). 
Although rare, DCIS and LCIS are recognised 
precursor lesions, as in the female breast. In contrast 
to females, columnar cell lesions, recognized 
precursor lesions of low grade lesions in the female 
breast, seem to be very rare in the male breast 
(Verschuur-Maes et al., 2014). 
 
Invasive micropapillary male breast cancer, a common histotype in the male breast. 
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Solid pattern of invasive ductal male breast cancer, a common histotype in the male breast. 
 
 
Invasive lobular male breast cancer, a rare histotype in the male breast. 
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Adenoid cystic male breast cancer, a rare histotype in the male breast. 
Treatment 
As MBC is rare, there are few clinical trials 
specifically focused on gender-orientated treatment; 
many clinical recommendations in MBC are 
therefore derived from studies performed in female 
breast cancer. Surgery is the first choice of treatment 
and most men undergo modified radical mastectomy 
with axillary lymph node dissection or sentinel node 
biopsy (Giordano, 2005). This is primarily due to a 
paucity of breast tissue in men as well as the fact that 
male BC usually occurs in central locations. Post-
surgical radiation criteria are extrapolated from 
female breast cancer studies. Although postoperative 
radiation is often routinely utilized in all stages of 
male breast cancer to help decrease the risk of local 
recurrence, this risk is believed to be small, 
especially in early stage disease (3% in stage 
1/2).Men with tumors ≥ 5 cm, T4 and lymph node 
positive disease are therefore more likely to receive 
post-surgery radiation (Chakravarthy and Kim, 
2002). 
Adjuvant endocrine therapy is standard treatment in 
MBC patients because the majority is hormone 
receptor positive. Many retrospective series have 
evaluated the effectiveness of tamoxifen 
(Nolvadex®; AstraZeneca Pharmaceuticals, 
http://www.astrazeneca-us.com) in MBC, showing a 
reduced risk of breast cancer recurrence and death in 
the metastatic and adjuvant setting. The role of 
aromatase inhibitors in the adjuvant setting for male 
patients is limited (Giordano, 2005) and their use as 
monotherapy or in combination with gonadotropin-
releasing hormone (GnRH) analogues is largely 
restricted to the metastatic stage of the disease 
(Zagouri et al., 2015) 
Given the established benefit of chemotherapy in 
women and the limited suggestive evidence in men, 
most clinicians use similar guidelines for adjuvant 
chemotherapy in male and female patients 
(Giordano, 2005). 
Prognosis 
The 5-year and 10-year relative survival rate for men 
with breast cancer is 84 and 72 percent, respectively 
(Howlader et al., 2016). Tumor stage is determined 
using the American Joint Committee on Cancer 
classification system, which considers tumor size, 
nodal involvement, and distant metastases. More 
than 40% of men with breast cancer present with 
stage 3/4 disease and therefore men have a worse 
overall survival but similar disease specific survival 
compared to women (Giordano, 2005). When MBC 
is diagnosed early, preferable when only DCIS is 
present, the tumors are mostly low to intermediate 
grade and the occurrence of distant metastasis is very 
unlikely (Ruddy and Winer, 2013). 
Prognostic factors that have been evaluated include 
the size of the lesion, mitotic index, tumor grade, 
lymph node status and molecular type, all of which 
correlate well with prognosis (Giordano et al., 2004; 
Ruddy and Winer, 2013; Kornegoor et al., 2012a). 
Based on numbers from 2009, node negative MBC 
have a five-year survival rate of 90%, compared with 
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65% five-year survival rate for node positive MBC 
(Fentiman, 2009). Also, grade 1 patients have a five-
year survival of 76%, dropping to 65% for those with 
grade 2 tumours and 43% for grade 3 MBC 
(Fentiman, 2009). In more recent studies, ER 
negativity (Ruddy and Winer, 2013; Abreu et al., 
2016), fibrotic focus >8 mm, hypoxia-inducible 
factor-1α overexpression and nuclear area 
(Kornegoor et al., 2012a; Veta et al., 2012) appear to 
be prognostic factors in MBC too. There is no or 
little evidence of a correlation between HER2, Ki67, 
PR or lymphovascular invasion and prognosis 
(Ruddy and Winer, 2013). 
Prognostic models that have been developed for 
FBC like the Multivariate Prognostic Index 
(consisting of mitotic index, tumour size and lymph 
node status), Nottingham Prognostic Index 
(consisting of grade, tumour size and lymph node 
status), Adjuvant! and Predict seem to perform quite 
well for MBC patients too (van der Pol et al., 2016). 
The combination of Bcl2 expression and mitotic 
index on the other hand, as opposed to FBC does not 
predict survival in MBC (Lacle et al., 2013). 
Interestingly, a multicenter international study that 
pooled data from 13 cancer registries found that 
12.5% of 3409 MBC survivors went on to develop a 
different (non-breast) cancer, and that risk of new 
primary cancers was elevated in the small intestine, 
rectum, pancreas, skin (non-melanoma), prostate, 
and lymphatics/blood. Other more recent studies 
have confirmed an elevated risk for other cancers in 
MBC survivors (Ruddy and Winer, 2013). 
Genetics 
Note 
The majority of MBC cases are sporadic, with many 
different oncogenes and tumor suppressor genes 
involved, while 10% are estimated to be due to an 
inherited predisposition (Rizzolo et al., 2013). In 
comparison with FBC there is a larger proportion of 
BRCA2 germline mutation carriers, (occurring in 
10% of MBC), and underrepresentation of BRCA1 
germline mutation carriers (found in only 1%). 
PALB2 and CHEK2 mutations have been reported 
in families with MBC. The contribution of BRIP1 
and RAD51C mutations to breast cancer 
predisposition in males seems to moderate compared 
with CHEK2 and PALB2. The androgen receptor 
(AR) gene and the cytochrome p540c17α gene 
(CYP17) have been suggested to play a role in MBC 
predisposition but these results were not supported 
by additional studies. Lastly, besides in Klinefelter 
syndrome patients, MBC have been reported rarely 
in Li-Fraumeni, Cowden and Lynch syndrome 
patients (Deb et al., 2016). 
 
HYPERMETHYLATION  
Promoter hypermethylation is common in MBC and 
high methylation status correlates with aggressive 
phenotype and poor survival. ESR1 and GSTP1 
promoter hypermethylation seem to be involved in 
development and/or progression of high-grade 
MBC. Although FBC and MBC share a set of 
commonly methylated genes, many of the studied 
genes are less frequently methylated in male breast 
cancer, pointing towards possible differences 
between male and female breast carcinogenesis 
(Kornegoor et al., 2012d). Unsupervised clustering 
of the most variable CpGs among MBC revealed two 
stable epitypes, designated ME1 and ME2, closely 
associated with the transcriptional subgroups 
luminal M1 and M2 (see "Classification"). Tumors 
in the ME1 group were more proliferative and 
aggressive than ME2 tumors, and showed a tendency 
toward inferior survival. ME1 tumors also displayed 
hypermethylation of PRC2 (polycomb) target genes 
and high expression of EZH2, one of the core 
components of PRC2. Differential methylation 
patterns were not only seen between the MBC 
epitypes, but also between MBCs and FBCs that 
cluster together (Johansson et al., 2015). 
Cytogenetics 
Cytogenetics Molecular 
Cytogenetic data in MBC are largely based on 
comparative genomic hybridization (CGH) studies 
preceded by a handful of small-scale karyotyping 
and microsatellite marker studies (Mitchell, 1990; 
Gudmundsson et al., 1995; Wingren et al., 1997; 
Rudas et al., 2000). Genomic gains are more 
common in MBC than in FBC and often involve 
whole chromosome arms, while losses of genomic 
material are less frequent (Tommasi et al., 2010; 
Johansson et al., 2011). The most common 
aberrations are similar between the genders, but 
high-level amplifications are more common in FBC 
(Johansson et al., 2011). Chromosomal gains are 
most frequent at 1q (~50%), 8q (~50%), 11q (~40%), 
16p (~40%), 17q (~40%), 20q (~30%), 7q (~20%) 
and Xp (~20%). Losses are most commonly 
observed at 8p (~40%), 11q (~40%), 13q (~30%), 
16q (~30%), 17p (~30%),1p (~20%) and 22q (20%) 
(Rudlowski et al., 2006; Tommasi et al., 2010; 
Johansson et al., 2011; Piscuoglio et al., 2016). 
Gains at 16p, 20q and Xq and losses at 13q correlate 
significantly with a higher degree of cytogenetic 
complexity (Rudlowski et al., 2006). In MBC 
chromosome 17 shows less complex rearrangements 
and fewer copy number changes compared to FBC. 
Frequent gains of 17q, encompassing two distinct 
amplicons, and losses of 17p were observed, but no 
whole chromosome 17 polyploidies (Lacle et al., 
2015). Copy number loss on 16q is less frequent in 
MBC than FBC and, in combination with 16p gain, 
identifies a group of MBC with low propensity to 
develop lymph node metastases (Lacle et al., 2013).  
Using fluorescence in situ hybridization (FISH) and 
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multiplex ligation dependent probe amplification 
(MLPA), gain or amplification of ERBB2, MYC, 
CCDN1, TRAF4, CDC6 and MTDH have been 
described in MBC (Bloom et al., 2001; Bärlund et 
al., 2004; Rudlowski et al., 2004; Kornegoor et al., 
2012c; Schildhaus et al., 2013). Using next 
generation sequencing, high-level amplifications of 
8p11.23 (14%, including FGFR1 and ZNF703), 
8q24.21 (17%, encompassing MYC), 17q23.2 (3%, 
including PPM1D), and 20q13.2 (3%, encompassing 
AURKA) were observed, as were homozygous 
deletions in CDKN2A (2%) and ATM 
(2%)(Piscuoglio et al., 2016).  
Translocations have not been systematically studied 
in MBC. One of the best known translocations in a 
specific subtype of female breast cancer (secretory 
type), a recurrent chromosomal translocation 
t(12;15)(p13;q25) leading to the formation of the 
ETV6 / NTRK3 fusion gene has been described in 
secretory MBC as well (Arce et al., 2005).  To our 
knowledge, only nine previous articles deal with 
adenoid cystic carcinoma (ACC) in the male breast 
but none of these studies have reported on the well-
known recurrent translocation t(6;9)(q22-23;p23-24) 
in FBC, resulting in a fusion of the two transcription 
factor genes MYB and NFIB (Persson et al., 2009; 
Tang et al., 2015).  
Genes involved and 
proteins 
Note 
The number of genetic alterations in (male) breast 
cancer is immense and it is therefore not possible to 
elaborate on all of them. A selection was made based 
on the aberration frequency and the amount of 
evidence/literature present. Several of the 
genes/proteins involved in MBC have already been 
described in female "Breast: Ductal carcinoma". 
These will not be repeated here (HER2/ERBB2, 
FGFR1, BRCA1, PTEN, ATM and CDH1). 
BRCA2 (breast cancer 2, early onset) 
Location 
13q13.1 
DNA / RNA 
The BRCA2 gene is composed of 27 exons. The 
structure and function of BRCA2 have extensively 
been described elsewhere 
(http://atlasgeneticsoncology.org/Genes/BRCA2ID
164ch13q13.html) and will therefore not be repeated 
here. 
Protein 
Multiple population-based studies have shown that 
4-15 % of men with breast cancer carry deleterious 
BRCA2 mutations (Ferzoco and Ruddy, 2016). By 
the age of 80 years, the cumulative risk of breast 
cancer in male BRCA2 germline mutation carriers 
has been estimated at 7% (Thompson et al., 2001). 
Among men with a family history of breast and/or 
ovarian cancer, reported mutation frequencies are 
generally higher. In the largest study so far 
comprising 642 families with MBC (these families 
had at least one additional case of FBC or ovarian 
cancer), BRCA1/2 mutation prevalence was 35.8% 
(95% CI: 32.2% to 39.6%) for MBC with at least one 
FBC or ovarian cancer in the family. BRCA2 
mutations were found more frequently (13-65%) 
than BRCA1 mutations (3-9%) in families without 
occurrence of ovarian carcinoma. In cases where 
additional ovarian carcinoma cases were present in 
the family, a similar prevalence of mutations was 
found in BRCA1 (23-27%) and BRCA2 (27-
30%)(Kast et al., 2016). In addition, there are 
populations who carry founder mutations that are 
significantly more common. For example, the 
BRCA2 999del5 founder mutation is implicated in 
over 40 % of Icelandic MBC cases (Thorlacius et al., 
1996). This mutation, a 5 bp deletion in exon 9 
starting at nucleotide 999, leads to a stop codon at 
nucleotide 1047 and to premature truncation of 
protein translation. Among BRCA2 MBCs, grade 
significantly decreases with increasing age at 
diagnosis. Compared with BRCA2 FBCs, BRCA2 
MBCs are of significantly higher stage and higher 
grade (Silvestri et al., 2016). 
PALB2 (partner and localizer of 
BRCA2) 
Location 
16p12.2 
Protein 
PALB2 (partner and localizer of BRCA2) plays a 
critical role in homologous recombination repair 
(HRR) through its ability to recruit BRCA2 and 
RAD51 to DNA breaks. The 1,186-amino acid 
protein has a calculated molecular mass of about 130 
kD, contains an N-terminal coiled coil domain and a 
C-terminal WD40 repeat domain that interacts with 
BRCA2 and RAD51. Inherited heterozygosity for 
this gene has been associated with an increased risk 
of breast cancer. Additionally, biallelic mutations of 
PALB2 have been linked to Fanconi anemia, which 
also has an increased risk of developing malignant 
disease.   
 
PALB2 mutations have been found in families with 
both FBC and MBC, suggesting that this gene may 
be involved in MBC risk (Rahman et al., 2007; 
Garcèa et al., 2009). Moreover, PALB2 
heterozygotes are 4-fold more likely to have a male 
relative with breast cancer (Casadei et al., 2011). 
Based on a handful of studies, PALB2 may have a 
role as moderate-penetrance gene in MBC at a 
comparable extent as for female breast cancer 
(Rizzolo et al., 2013). A recent study added strength 
to this evidence by performing whole exome 
sequencing in germline DNA of 1 male and 2 female 
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BRCA1/2 mutation-negative breast cancer cases 
from a pedigree showing a first-degree family 
history of MBC and targeted PALB2 sequencing in 
48 high-risk, BRCA1/2 mutation-negative MBC 
cases (Silvestri et al., 2016). According to this 
largest study so far, the frequency of PALB2 
pathogenic mutations in high-risk MBC cases is 
higher than that observed in high-risk FBC cases (ie, 
4% vs 1%). 
CHEK2 (CHK2 checkpoint homolog 
(S. pombe)) 
Location 
22q12.1 
Protein 
The protein encoded by checkpoint kinase 2 
(CHEK2) is a cell cycle checkpoint regulator and 
putative tumor suppressor. It contains a forkhead-
associated protein interaction domain essential for 
activation in response to DNA damage and is rapidly 
phosphorylated in response to replication blocks and 
DNA damage. When activated, the encoded protein 
is known to inhibit CDC25C phosphatase, 
preventing entry into mitosis, and has been shown to 
stabilize the tumor suppressor protein TP53, leading 
to cell cycle arrest in G1. In addition, this protein 
interacts with and phosphorylates BRCA1, allowing 
BRCA1 to restore survival after DNA damage. 
Mutations in this gene have been linked with Li-
Fraumeni syndrome, a highly penetrant familial 
cancer phenotype usually associated with inherited 
mutations in TP53. Also, mutations in CHEK2 are 
thought to confer a predisposition to sarcomas, 
breast cancer, and brain tumors. This nuclear protein 
is a member of the CDS1 subfamily of 
serine/threonine protein kinases. Several transcript 
variants encoding different isoforms have been 
found for this gene.  
It has been estimated that the CHEK2 1100delC 
mutation accounts for 9% of MBC cases and confers 
about 10-fold increase of breast cancer risk in men 
lacking BRCA1 and BRCA2 mutations (Meijers-
Heijboer et al., 2002). Other studies have reported 
lower CHEK2 mutation frequencies in MBC, 
ranging from 2% to 4% (Sodha et al., 2004; 
Syrjäkoski et al., 2004; Wasielewski et al., 2009). 
AR (Androgen Receptor 
(dihydrotestosterone receptor; 
testicular feminization; spinal and 
bulbar muscular atrophy; Kennedy 
disease)) 
Location 
Xq12 
Protein 
The androgen receptor (AR) gene is more than 90 kb 
long and encodes a protein that has 3 major 
functional domains: the N-terminal domain, DNA-
binding domain, and androgen-binding domain. The 
protein functions as a steroid-hormone activated 
transcription factor. Upon binding the hormone 
ligand, the receptor dissociates from accessory 
proteins, translocates to the nucleus, dimerizes, and 
then stimulates transcription of androgen responsive 
genes. This gene contains 2 polymorphic 
trinucleotide repeat segments that encode 
polyglutamine and polyglycine tracts in the N-
terminal transactivation domain of its protein. Two 
alternatively spliced variants encoding distinct 
isoforms have been described.  
Androgen hyposensitivity caused by either AR 
mutations or long CAG repeats might be a causal 
factor for MBC (Di Lauro et al., 2015). Mutations in 
the AR gene have been described in MBC and were 
shown to be associated with complete androgen 
insensitivity (CAIS) (Wooster et al., 1992; 
Lobaccaro et al., 1993). Also, variations of the 
polyglutamine (CAG) repeat within exon 1 of AR 
were demonstrated in MBC, with shorter CAG tracts 
associated with increased AR transcriptional 
activity, and longer CAG tracts resulting in a 
suboptimal ligand-mediated stimulation of AR 
(Young et al., 2000; Song et al., 2012). 
Immunohistochemistry studies of MBC samples 
reported AR expression in a range of 34-95% (Di 
Lauro et al., 2015). In addition to this striking 
variability, controversy exists, and conflicting data 
were reported, on the association between AR 
expression and disease stage and/or survival 
outcomes. 
CYP17A1 (cytochrome P450 family 
17 subfamily A member 1) 
Location 
10q24.32 
Protein 
This gene encodes a member of the cytochrome 
P450 superfamily of enzymes. The cytochrome P450 
proteins are monooxygenases which catalyze many 
reactions involved in drug metabolism and synthesis 
of cholesterol, steroids and other lipids. This protein 
localizes to the endoplasmic reticulum. It has both 
17alpha-hydroxylase and 17,20-lyase activities and 
is a key enzyme in the steroidogenic pathway that 
produces progestins, mineralocorticoids, 
glucocorticoids, androgens, and estrogens. 
Mutations in this gene are associated with isolated 
steroid-17 alpha-hydroxylase deficiency, 17-alpha-
hydroxylase/17,20-lyase deficiency, 
pseudohermaphroditism, and adrenal hyperplasia.  
A polymorphic T to C substitution has been 
described that creates an additional CCACC type 
promoter site 34 bp upstream from the site of 
initiation of translation (Carey et al., 1994). It is 
thought that the additional promoter site may 
increase the rate of transcription of the gene and 
thereby increase enzyme activity. Serum oestradiol 
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levels are higher in women hetero- and homozygous 
for the C allele of the CYP17 gene (Feigelson et al., 
1998). A germline T to C variant in CYP17 has been 
associated with an increased male breast cancer risk 
(Young et al., 1999) with an odds ratio (OR) of 2.10 
(95% confidence interval 1.04-4.27). A subsequent 
study, however, did not observe a significant 
association between MBC risk and CYP17 
genotype, but the frequency of the CC genotype was 
higher among carriers of the BRCA2 999del5 
Icelandic founder mutation (33.3%) than non-
carriers (16.7%; Gudmundsdottir et al., 2003). 
PIK3CA (phosphoinositide-3-kinase, 
catalytic, alpha polypeptide) 
Location 
3q26.32 
Protein 
The PIK3CA gene is composed of 21 exons, 20 of 
them coding exons, and encodes a cytoplasmic 
protein of 1,068 amino acid residues. The PIK3CA 
gene encodes the p110alpha protein which is a 
catalytic subunit of the class I PI 3-kinases (PI3K). 
Class I PI3K are heterodimeric molecules composed 
of a p110 catalytic subunit and a regulatory subunit. 
PI 3-Kinases (phosphoinositide 3-kinases, PI3Ks) 
coordinate a diverse range of cell functions including 
proliferation, cell survival, degranulation, vesicular 
trafficking and cell migration.  
PIK3CA activating mutations show a high 
prevalence in female breast cancer (40.1% coding 
mutations in METABRIC)(Pereira et al., 2016) and 
are associated with higher age at diagnosis, hormone 
receptor positivity, HER2 negativity, lower tumor 
grade and stage, and lymph node negativity. 
PIK3CA mutations have been associated with 
significantly longer metastasis-free survival, 
especially in the PR-positive and HER2-positive 
subgroups (Cizkova et al., 2012), may have 
independent driver properties in a HER2-positive 
context, and have been implicated in resistance to 
anti-HER2 therapies (Nahta and Esteva, 2006). The 
majority of mutations occur at three hotspots (E542, 
E545, or H1047), making these ideal targets for 
therapeutic development. MBC less frequently 
harbor PIK3CA mutations (20%) than ER-
positive/HER2-negative FBC but nevertheless it is 
the most frequently mutated gene in MBC. Almost 
all reported PIK3CA mutations in MBC affected the 
hotspots (Piscuoglio et al., 2016). 
GATA3 (GATA binding protein 3) 
Location 
10p14 
Protein 
The GATA3 gene contains 6 exons. The full length 
GATA3 protein contains either 443 amino acids 
(isoform a) or 444 amino acids (isoform b), 
corresponding to molecular weights of 47,9 kDa and 
48,0 kDa respectively. The GATA3 protein contains 
two zinc finger motifs as well as two transactivation 
domains. The N-terminal zinc finger is known to 
stabilize DNA binding and interact with other zinc 
finger proteins, whereas the C-terminal zinc finger 
binds DNA. As such, GATA3 is a member of the 
GATA family of zinc-finger binding transcription 
factors that regulates the specification and 
differentiation of many tissue types including the 
breast.  
In the context of FBC, GATA3 is intimately 
associated with luminal cell identity and function, 
and mutated in 11% of patients (Pereira et al., 2016). 
A truncating splice variant at position 308 is by far 
the most prevalent hotspot (23% of GATA3 
mutations). In MBC, GATA3 is mutated in 15% of 
patients, and restricted to the luminal B-like breast 
cancer subtype. These mutations are associated with 
worse disease-free survival and interestingly, the 
pattern of mutations found in males does not 
resemble that of female breast cancers. In fact, the 
majority of GATA3 mutations found in MBC are 
frameshift mutations and do not affect the 
aforementioned hotspot (Piscuoglio et al., 2016). 
TP53 (Tumour protein p53 (Li-
Fraumeni syndrome)) 
Location 
17p13.1 
Protein 
The structure and function of the TP53 transcription 
factor have extensively been described elsewhere 
(http://atlasgeneticsoncology.org/Genes/GC_TP53.
html) and will therefore not be repeated here. 
Mutations in the TP53 gene can be found in 50% of 
human cancers. More than 80% of TP53 mutations 
are missense mutations that lead to the synthesis of a 
stable oncogenic protein that accumulates in the 
nucleus of tumor cells. In The Cancer Genome Atlas 
(TCGA) project, six MBC were included, of which 
none had TP53 mutations (Cancer Genome Atlas 
Network, 2012). A massively parallel sequencing 
study based on 59 MBC detected a lower frequency 
of TP53 mutations in ER-positive/HER2-negative 
MBC compared with ER-positive/HER2-negative 
FBC (7% vs. 22%)(Piscuoglio et al., 2016). 
CCND1 (B-cell leukemia/lymphoma 1) 
Location 
11q13.3 
Protein 
he CCND1 gene contains 5 coding exons. The 
structure and function of CCND1 (Cyclin D1) have 
extensively been described elsewhere 
(http://atlasgeneticsoncology.org/Genes/BCL1ID36
.html) and will therefore not be repeated here. The 
CCND1 gene is amplified in 12-18% of MBC 
(Bärlund et al., 2004; Kornegoor et al., 2012;  
Rizzolo et al., 2016) and amplification is associated 
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with poor prognosis (Kornegoor et al., 2012). Cyclin 
D1 was shown to be a selective repressor of 
androgen-dependent signaling and androgen 
receptor function (Comstock et al., 2011) and a 
driver of androgen-dependent DNA damage repair, 
thereby contributing to radioresistance (Casimiro et 
al., 2016). 
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